Dapagliflozin, used to treat diabetes, can also treat heart failure in patients with and without diabetes (the DAPA-HF Study, published in The Lancet)
Please note unusual embargo: 13:15H Barcelona time Thursday 19 September Dapagliflozin, a drug that is already used to successfully treat type 2 diabetes (T2D) and prevent development of heart failure, can also be used to treat pre-existing heart failure, even in patients without T2D. These are the conclusions of research presented at this year’s Annual Meeting